News
MedPage Today on MSN5d
Palopegteriparatide Benefits Sustained in Adults With Chronic HypoparathyroidismORLANDO -- Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback